Adjuvance Technologies Overview

Adjuvance Technologies is a privately held biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in vaccine adjuvant design and manufacturing. Adjuvants are critical components that are added to many vaccines to improve the immune response. Adjuvance Technologies has developed the ability to synthesize saponin adjuvants such as QS-21, a critical component of the AS01 adjuvant developed by GSK. In addition, we have synthesized a novel analogue, TQL1055, with improved attributes compared to QS-21.